Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.36 |
| ▸ | TTK | P33981 | 4/20 | 0.34 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 4/20 | 0.34 |
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.34 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22124871 | 0.96 | SYK (0.39) | SYKTTKMAPKAPK5GSK3ASRC | |
| SCHEMBL22124653 | 0.92 | SYK (0.39) | SYKTTKMAPKAPK5PTK6AXL | |
| SCHEMBL22124815 | 0.90 | TTK (0.39) | SYKTTKMAPKAPK5PTK6BRAF | |
| SCHEMBL30385354 | 0.90 | SYK (0.36) | SYKTTKMAPKAPK5PTK6AXL | |
| Hydrochloric Acid SCHEMBL30193386 | 0.90 | TTK (0.38) | SYKTTKMAPKAPK5PTK6BRAF | |
| SCHEMBL22124604 | 0.90 | PTK6 (0.41) | SYKMAPKAPK5PTK6MCHR1 | |
| SCHEMBL30349525 | 0.90 | SYK (0.36) | SYKTTKMAPKAPK5PTK6AXL | |
| SCHEMBL22124567 | 0.90 | SYK (0.36) | SYKTTKMAPKAPK5PTK6AXL | |
| SCHEMBL22123578 | 0.90 | SYK (0.36) | SYKTTKMAPKAPK5PTK6AXL | |
| SCHEMBL30171566 | 0.90 | PTK6 (0.41) | SYKMAPKAPK5PTK6MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SYK 939/4885TTK 4573/4885MAPKAPK5 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.